Entering text into the input field will update the search result below

Chimerix's (CMRX) CEO Michelle Berrey on Q4 2017 Results - Earnings Call Transcript

Mar. 01, 2018 2:39 PM ETChimerix, Inc. (CMRX) Stock1 Comment
SA Transcripts profile picture
SA Transcripts

Chimerix Inc. (NASDAQ:CMRX) Q4 2017 Earnings Conference Call March 1, 2018 8:30 AM ET


Michelle LaSpaluto - Senior Director of Accounting

Michelle Berrey - President and Chief Executive Officer

Garrett Nichols - Chief Medical Officer

Timothy Trost - SVP, Chief Financial Officer

Linda Richardson - Chief Strategy and Commercial Officer


David Lebowitz - Morgan Stanley

Katherine Xu - William Blair

Phil Nadeau - Cowen and Company

Ed White - H.C. Wainwright

Yigal Nochomovitz - Citigroup

Philomena Kamya - Stifel, Nicolaus & Company


Good morning. Welcome to the Chimerix Conference Call discussing the financial results of the Fourth Quarter and Full-Year 2017. Please be advised that today’s call is being recorded at Chimerix’s request.

I would now like to turn the call over to Michelle LaSpaluto from Chimerix.

Michelle LaSpaluto

Thank you, and welcome to the Chimerix fourth quarter and full-year 2017 financial results conference call. This morning at 7:30 Eastern Time, we issued a press release containing financial results and other updates for the fourth quarter and full-year 2017. The press release is available on the company’s website at www.chimerix.com. You may also access today’s call via webcast on the Investors section of the Chimerix website. An archive of the webcast will be available approximately two hours after the conclusion of the event.

With me on today’s call are Michelle Berrey, President and CEO; Garrett Nichols, Chief Medical Officer; Linda Richardson, Chief Strategy and Commercial Officer; and Tim Trost, Chief Financial Officer.

Before we begin, I’d like to remind you that the statements made on today’s call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including the possibility there may not be a viable continued development for brincidofovir, that the FDA and other regulatory authorities

Recommended For You

Comments (1)

Reyan profile picture
Quite impressive CC full of planed data and trials read out releasing in 2018. BARDA funding is coming. This company is still having a strong cash balance. And it's trading on cash value at current $5.50 range. SP creeping up for a few days reaching 6-9 months high. It looks like breaking 52 weeks high in sight.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CMRX Stock

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CMRX

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.